Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 Dupixent is the only biologic to show… Read More
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with… Read More
Top-tier investor syndicate led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital. Gandeeva will use the funding to… Read More
VANOUVER & ALBERTA — Gowling WLG is pleased to announce that Dan Misutka has joined the firm as a partner in the Administrative Law Group. He will split his time between… Read More
Approval based on results from Phase 3 CROWN trial, showing LORVIQUA reduced risk of disease progression or death by 72% in newly diagnosed individuals compared to XALKORI® (crizotinib) NEW YORK… Read More
